Clinical Trials
86 trialsASC4START
Novartis
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.
SENTRY
Karyopharm Therapeutics Inc
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
MK-3543-017
Merck Sharp & Dohme LLC
GIV-IN-PV
Italfarmaco
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
TRANSFORM-1
AbbVie
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Orca-T
Orca Biosystems, Inc.
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
STIMULUS-MDS2
Novartis
TRANSFORM-2
AbbVie
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
PANTHER
Takeda
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
FREEDOM2
Celgene
SURPASS ET
PharmaEssentia
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia
VERIFY
Protagonist Therapeutics, Inc.
THRIVE
Protagonist Therapeutics, Inc.
INDEPENDENCE
Celgene
POLARIS-2
Ascentage Pharma Group Inc.
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
PREFER-HMA
Otsuka Australia Pharmaceutical Pty Ltd
FREEDOM
Celgene
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PharmaEssentia Japan K.K.
A Study to Evaluate P1101 in Japanese PV Patients
PharmaEssentia Japan K.K.
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Astex Pharmaceuticals, Inc.
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
AB Science
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
HATCY
Kiadis Pharma
MEDALIST
Celgene
OPTIC-2L
Takeda
PAC326
CTI BioPharma
RESPONSE-2
Novartis
ENESTPath
Novartis
CONTI-PV
AOP Orphan Pharmaceuticals AG
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
ENESTnd
Novartis
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH